Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 11:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 198 matching trials from the live ClinicalTrials.gov search.
Conditions
Liver Metastases, Lung Metastases, Recurrent Melanoma, Stage IV Melanoma, Tumors Metastatic to Brain
Interventions
ipilimumab, stereotactic radiosurgery, laboratory biomarker analysis
Biological · Radiation · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Gastrointestinal Stromal Tumor
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
Biological · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
Interventions
3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Calaspargase Pegol, Cytarabine, Dexamethasone, Hydrocortisone Sodium Succinate, Lumbar Puncture, Mercaptopurine, Methotrexate, Nivolumab, Pegaspargase, Vincristine Sulfate
Radiation · Drug · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 30 Years
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
213
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 151 more
Conditions
Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Acral Lentiginous Melanoma, Unresectable Melanoma, Unresectable Mucosal Melanoma
Interventions
Ipilimumab, Nivolumab, Patient Observation, Pembrolizumab
Biological · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
482
States / cities
Fairhope, Alabama • Mobile, Alabama • Fairbanks, Alaska + 330 more
Conditions
Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Duvelisib, Nivolumab, Positron Emission Tomography, Punch Biopsy
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
17
States / cities
Phoenix, Arizona • Aurora, Colorado • Coral Gables, Florida + 12 more
Conditions
Melanoma
Interventions
Ipilimumab, Radiation Therapy
Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Stanford, California
Conditions
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Interventions
Biospecimen Collection, Computed Tomography, Echocardiography Test, Nivolumab, Observation Activity, Positron Emission Tomography
Procedure · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
903 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
884
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 638 more
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Melanoma, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Stage IV Melanoma, Stage IV Non-small Cell Lung Cancer
Interventions
ipilimumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Locally Advanced Bone Sarcoma, Locally Advanced Dedifferentiated Liposarcoma, Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Soft Tissue Sarcoma, Metastatic Bone Sarcoma, Metastatic Liposarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Metastatic Unresectable Sarcoma, Pleomorphic Liposarcoma, Stage III Bone Sarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Bone Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Bone Sarcoma AJCC v7, Stage IVB Bone Sarcoma AJCC v7, Unresectable Bone Sarcoma, Unresectable Dedifferentiated Liposarcoma, Unresectable Liposarcoma, Unresectable Malignant Gastrointestinal Stromal Tumor, Unresectable Soft Tissue Sarcoma
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
651
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • Little Rock, Arkansas + 402 more
Conditions
Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
Interventions
Ipilimumab, Nivolumab, Pembrolizumab, Quadrivalent Inactivated Influenza Vaccine, Resection, Nivolumab + Relatlimab
Biological · Procedure
Lead sponsor
Carlo Contreras
Other
Eligibility
18 Years to 99 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lung, Salivary Gland Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v8, Stage IVA Major Salivary Gland Cancer AJCC v8, Stage IVB Major Salivary Gland Cancer AJCC v8, Stage IVC Major Salivary Gland Cancer AJCC v8
Interventions
Nivolumab, Ipilimumab, Stereotactic Body Radiation Therapy
Biological · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8
Interventions
Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
92
States / cities
Irvine, California • Los Angeles, California • Newport Beach, California + 72 more
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Mucosal Melanoma, Unresectable Cutaneous Melanoma, Unresectable Melanoma
Interventions
Ipilimumab, Nivolumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
638
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 392 more
Conditions
ALK Gene Rearrangement, EGFR Gene Mutation, Locally Advanced Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Ipilimumab, Nivolumab, Radiation Therapy
Biological · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Merkel Cell Carcinoma, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8
Interventions
Ipilimumab, Nivolumab, Radiation Therapy
Biological · Radiation
Lead sponsor
Claire Verschraegen
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipilimumab, Nivolumab, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter
Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma, Human Papillomavirus Infection, Recurrent Cervical Carcinoma, Stage IVA Cervical Cancer AJCC v6 and v7, Stage IVB Cervical Cancer AJCC v6 and v7
Interventions
Ipilimumab, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
5
States / cities
Duarte, California • Sacramento, California • South Pasadena, California + 2 more
Conditions
Cancer, Multiple Indications
Interventions
Anti-PDL-1 antibody
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
11
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Conditions
Prostate Cancer, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma
Interventions
Ipilimumab, Nivolumab, Enzalutamide
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions
Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Radiation Therapy, Sigmoidoscopy, Total Mesorectal Excision
Procedure · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
213
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 145 more
Conditions
Recurrent Melanoma, Stage IV Skin Melanoma
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Pharmacological Study, Stereotactic Body Radiation Therapy
Biological · Other · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Interventions
Biospecimen Collection, Bleomycin Sulfate, Brentuximab Vedotin, Computed Tomography, Cyclophosphamide, Dacarbazine, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Fludeoxyglucose F-18, Involved-site Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Prednisolone, Prednisone, Procarbazine Hydrochloride, Questionnaire Administration, Vinblastine Sulfate, Vincristine Sulfate
Procedure · Biological · Drug + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
5 Years to 60 Years
Enrollment
1,875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
404
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 298 more
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Recurrent Cervical Carcinoma, Stage IV Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7, Stage IVB Cervical Cancer AJCC v6 and v7
Interventions
Laboratory Biomarker Analysis, Nivolumab
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
331
States / cities
Birmingham, Alabama • Anchorage, Alaska • Hot Springs, Arkansas + 220 more
Conditions
Melanoma, Unresectable Melanoma
Interventions
Sarilumab, Ipilimumab Injection, Nivolumab/Relatlimab
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York